Monoclonal Antibody Therapeutics Market, by Source (Human, Humanized, Chimeric, and Others), by Therapeutic Application (Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Jan 2019 |
  • Pages : 187 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Monoclonal Antibody Therapeutics Market - Insights

Monoclonal antibodies are a type of immunotherapy, which are made in a laboratory and are several copies of a single antibody. Several monoclonal antibodies to treat inflammatory, cancer, and other diseases have been approved by the U.S. Food & Drug Administration (FDA). Depending on the source, there are four types of monoclonal antibodies: Murine, Chimeric, Humanized, and Human. Murine antibodies are entirely derived from a murine source, chimeric antibodies contain variable regions from murine origin and constant regions from human origin. Humanized antibodies are derived from a human source with a small part of a mouse or rat monoclonal antibody and human antibodies are entirely derived from a human source. Monoclonal antibodies are majorly used in cancer treatment along with certain inflammatory, infectious, and other diseases. Depending upon the functions of monoclonal antibodies (for cancer) they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available monoclonal antibodies include, Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Increasing drug approvals and launch of novel monoclonal antibodies for treatment of various diseases such as cancer are expected to boost the market growth over the forecast period

Frequent approvals of novel monoclonal antibodies and their launches in developed economies are expected to significantly drive monoclonal antibody therapeutics market growth over the forecast period. Key players in the market have gained regulatory approvals and have launched their therapies in the market. For instance, in 2015, the U.S. FDA approved Darzalex, developed by Johnson & Johnson for multiple myeloma. Similarly, in 2017, Roche was granted accelerated approval to TECENTRIQ (atezolizumab) from the U.S FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy.

Moreover, approvals to several combination therapies are further expected to boost the global monoclonal antibody therapeutics market growth over the forecast period. For instance, in 2017, the U.S. FDA approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma. Moreover, different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1.

The global monoclonal antibody therapeutics market was valued at US$ 95,560.5 million in 2017, and is expected to witness a robust CAGR of 6.9% over the forecast period (2018–2026).

Figure No.1: Global Monoclonal Antibody Therapeutics Market Share, By Region (%), 2018 - 2026        

                                                                                                        Monoclonal Antibody Therapeutics  | Coherent Market Insights                                                                                        

Source: Coherent Market Insights Analysis (2017)

Ongoing research and development of monoclonal antibodies for various diseases is expected to boost growth of the global monoclonal antibody therapeutics market

Introduction and supposed success of monoclonal antibodies and other biological products has spurred the interest of manufacturers in these therapies. Success of popular monoclonal antibodies such as Avastin, Herceptin, and Rituxan (revenues as US$ 6.8 Bn, US$ 7.1 Bn, and US$ 5.9 Bn respectively in 2017 globally) has spurred manufacturers’ interest in these therapies. Leading manufacturers have resorted to boosting pipeline through various ways such as merger and acquisitions, partnerships, and collaboration. In 2016, AbbVie acquired Stemcentrx thereby adding rovalpituzumab tesirine (Rova-T) to its product portfolio in oncology segment. Cancer treatment (various types) is at the forefront of the monoclonal antibody research as leading manufacturers are focused on development of these drugs for cancer treatment. For instance, manufacturers such as Amgen, Inc. (e.g. Tezepelumab and others) and Novartis International AG (e.g. Ofatumumab and others) have several monoclonal antibody programs in the pipeline.

However, high costs of these products is a major concern (in regions with underdeveloped reimbursement facilities) in the healthcare system and to address this problem, manufacturers have resorted to biosimilar products. Biosimilars cost much lower than the original products as the cost of development is relatively low. Majority of the available monoclonal antibody therapeutics (cancer treatments) are expected to lose patent protection by 2020 and some by 2025. For instance, drugs such as Herceptin and Avastin are expected to lose patent protection in 2019. These factors are expected to restrain the global monoclonal antibody therapeutics market growth over the forecast period.

Some of the major players operating in the global monoclonal antibody therapeutics market include, Pfizer, Inc., Novartis International AG, Amgen, Inc., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eily, Lilly, and Company, and Bristol-Myers Squibb Company.

Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017, the U.S. Food & Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma, who have received two prior therapies. These factors are expected to support growth of the market over the forecast period.

Market Dynamics

Monoclonal antibody therapeutics market is driven by active research and development of novel drugs and significant number of new drug launches and approval. There are number of monoclonal antibodies in the pipeline, which are expected to receive approval over the forecast period. For instance, manufacturers such as Amgen, Inc., Novartis International AG, Merck & Co., Inc., Eily, Lilly, and Company, and others have several monoclonal antibodies in the pipeline. Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA), expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Key features of the study:

  • This report provides in-depth analysis of monoclonal antibody therapeutics  market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global monoclonal antibody therapeutics  market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Pfizer, Inc., Novartis International AG, Amgen, Inc., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eily, Lilly, and Company, and Bristol-Myers Squibb Company
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
  • The global monoclonal antibody therapeutics  market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the monoclonal antibody therapeutics  market

Detailed Segmentation:

  • Global Monoclonal Antibody Therapeutics Market, By Source:
    • Human
    • Humanized
    • Chimeric
    • Others
  • Global Monoclonal Antibody Therapeutics Market, By Therapeutic Application:
    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases
    • Hematological Disorders
    • Others
  • Global Monoclonal Antibody Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies  
    • Specialty Pharmacies
  • Global Monoclonal Antibody Therapeutics Market, By Geography:
    • North America
      • By Source:
        • Human
        • Humanized
        • Chimeric
        • Others
      • By Therapeutic Application:
        • Oncology
        • Autoimmune Diseases
        • Infectious Diseases
        • Hematological Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Specialty Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Source:
        • Human
        • Humanized
        • Chimeric
        • Others
      • By Therapeutic Application:
        • Oncology
        • Autoimmune Diseases
        • Infectious Diseases
        • Hematological Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Specialty Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Source:
        • Human
        • Humanized
        • Chimeric
        • Others
      • By Therapeutic Application:
        • Oncology
        • Autoimmune Diseases
        • Infectious Diseases
        • Hematological Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Specialty Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Source:
        • Human
        • Humanized
        • Chimeric
        • Others
      • By Therapeutic Application:
        • Oncology
        • Autoimmune Diseases
        • Infectious Diseases
        • Hematological Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Specialty Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • By Source:
        • Human
        • Humanized
        • Chimeric
        • Others
      • By Therapeutic Application:
        • Oncology
        • Autoimmune Diseases
        • Infectious Diseases
        • Hematological Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Specialty Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Source:
        • Human
        • Humanized
        • Chimeric
        • Others
      • By Therapeutic Application:
        • Oncology
        • Autoimmune Diseases
        • Infectious Diseases
        • Hematological Disorders
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
        • Specialty Pharmacies
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Novartis International AG
    • Amgen, Inc.
    • Sanofi S.A.
    • Merck & Co., Inc.
    • GlaxoSmithKline Plc
    • F. Hoffman-La Roche Ltd.
    • AbbVie, Inc.
    • Eily, Lilly, and Company
    • Bristol-Myers Squibb Company

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Source
      • Market Snippet, By Therapeutic Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Impact Analysis
    • Technological Evolution
    • PEST Analysis
    • Pipeline Analysis
    • Porter’s Analysis
  4. Global Monoclonal Antibody Therapeutics Market, By Source, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Human
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Humanized
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Chimeric
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
  5. Global Monoclonal Antibody Therapeutics Market, By Therapeutic Application, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Autoimmune Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Infectious Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Hematological Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
  6. Global Monoclonal Antibody Therapeutics Market, By Distribution Channel, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Specialty Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
  7. Global Monoclonal Antibody Therapeutics Market, By Regions, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2026
    • North America
      • Market Size and Forecast, By Source, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Source, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Source, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Source, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Source, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Source, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffman-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eily, Lilly, and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 37 figures on "Monoclonal Antibody Therapeutics Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.